Zobrazeno 1 - 9
of 9
pro vyhledávání: '"L A Jokubaitis"'
Autor:
L A, Jokubaitis
Publikováno v:
British journal of clinical practice. Supplement.
Fluvastatin, a new synthetic inhibitor of HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase, has been studied in several models to examine its effects when used in combination with other lipid-modifying agents such as derivatives of fibric aci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::07c829c9c9faff06f7aa9afed12e0d9e
https://pubmed.ncbi.nlm.nih.gov/19496270
https://pubmed.ncbi.nlm.nih.gov/19496270
Autor:
L A, Jokubaitis
Publikováno v:
British journal of clinical practice. Supplement.
Fluvastatin is the first synthetic 3-hydroxy-3-methylglutaryl coenzyme A (HMGCoA) reductase inhibitor to be approved for clinical use, and has been studied extensively in humans since 1986. It is structurally distinct from the other currently availab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::1ea66861d2b8fa59d1d07a214a31b908
https://pubmed.ncbi.nlm.nih.gov/19489169
https://pubmed.ncbi.nlm.nih.gov/19489169
Publikováno v:
Journal of internal medicine. Supplement. 736
In this preliminary report of a 20-week trial, 66 patients with non-insulin-dependent diabetes mellitus (NIDDM) and hyperlipidaemia who remained eligible after an 8-week dietary stabilization phase were randomly allocated to receive 20 mg of fluvasta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a4ccec5cade305656a1c0b7140106ab
https://pubmed.ncbi.nlm.nih.gov/7986302
https://pubmed.ncbi.nlm.nih.gov/7986302
Publikováno v:
American journal of hypertension. 6(11 Pt 2)
Fluvastatin sodium (Lescol) is the first synthetic 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA)-reductase inhibitor to be studied extensively in humans. Absorption of fluvastatin is complete and unaffected by the presence of food. Systemic exposur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a653d5fb9da7782bc7cc16507b13f4b
https://pubmed.ncbi.nlm.nih.gov/8297546
https://pubmed.ncbi.nlm.nih.gov/8297546
Publikováno v:
Drugs Affecting Lipid Metabolism ISBN: 9789401047463
Fluvastatin (FL), the first synthetic HMG-CoA reductase inhibitor, was administered to 946 hypercholesterolemic patients in four Phase III trials of 18 to 54 weeks duration. At 20 mg QPM, FL treatment resulted in a mean change in LDL-C of -20.5% (p 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::499fabb086eaf99593416904b57d0f03
https://doi.org/10.1007/978-94-011-1703-6_33
https://doi.org/10.1007/978-94-011-1703-6_33
Publikováno v:
Pharmaceutical Research; Jan2004, Vol. 21 Issue 1, p68-82, 15p
Autor:
Smedby, Örjan
Publikováno v:
Annals of Biomedical Engineering; May1998, Vol. 26 Issue 3, p391-397, 7p
Publikováno v:
Biopharmaceutics & Drug Disposition; 1995, Vol. 16 Issue 3, p211-219, 9p
A great deal of experimental, clinical and epidemiological data have been gathered to confirm the strict and causal correlation between plasma lipoproteins and coronary heart disease. However, as usually happens in research, many more interesting iss